journal article·2018-11-05Open access

MicroRNA-145-3p suppresses proliferation and promotes apotosis and autophagy of osteosarcoma cell by targeting HDAC4

Guangzhi Wu, Wei Yu, Minglei Zhang, Ruofeng Yin, Yan Wu, Qiang Liu

Abstract

Studies have shown that miR-145-3p functions as a tumor suppressor and is associated with tumor growth and metastasis. This study intends to uncover the mechanism of a tumor suppressor of miR-145-3p. The expressions of miR-194 in osteosarcoma cell lines and tissues were monitored by real-time PCR. The proliferation ability was examined by MTT assay. The apoptosis and autophagy of cells were monitored by flow cytometry and microcopy, respectively. The regulation of miR-145-3p on HDAC4 was determined by luciferase assays and western blot assay. The results showed that miR-145-3p was significantly reduced in the osteosarcoma compared with the normal bone tissue. Overexpression of miR-145-3p significantly attenuated the proliferation and induced the apoptosis and autophagy of osteosarcoma cells. Furthermore, we demonstrated that miR-145-3p has inhibited the malignant behavior of osteosarcoma by down-regulating HDAC4 expression. These findings suggested that miR-145-3p may act as a tumor suppressor in osteosarcoma. MiR-145-3p/HDAC4 may be a novel therapeutic target in treatment of osteosarcoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Histone Deacetylase Inhibitors Research · Epigenetics and DNA Methylation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hand Surgery, China-Japan Union Hospital, Jilin University, Changchun, China;

Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, China;

Department of Molecular Biology, Medical College, Suchow University, Suzhou, China

References (25)

Show source-provided references
1. 10.1007/978-1-4419-0284-9_110.1007/978-1-4419-0284-9_1 ↗
2. Wu PK · J Clin Oncol · 2009 · 39 · 514
3. 10.1126/science.111144410.1126/science.1111444 ↗
4. 10.1016/j.eururo.2013.11.04610.1016/j.eururo.2013.11.046 ↗
5. 10.1002/biof.2710.1002/biof.27 ↗
6. 10.1016/j.immuni.2007.03.00510.1016/j.immuni.2007.03.005 ↗
7. 10.1186/1471-2407-14-63010.1186/1471-2407-14-630 ↗
8. 10.1016/j.humpath.2014.01.01710.1016/j.humpath.2014.01.017 ↗
9. 10.1371/journal.pone.004490710.1371/journal.pone.0044907 ↗
10. 10.1016/j.jaci.2011.04.00510.1016/j.jaci.2011.04.005 ↗
11. 10.3892/or.2014.359110.3892/or.2014.3591 ↗
12. Zhou X · Int J Clin Exp Med · 2015 · 9 · 16890
13. 10.1002/ijc.2916810.1002/ijc.29168 ↗
14. 10.1038/sj.bjc.660557010.1038/sj.bjc.6605570 ↗
15. 10.3892/ol.2016.546210.3892/ol.2016.5462 ↗
16. 10.1038/cddis.2017.49310.1038/cddis.2017.493 ↗
17. 10.18632/oncotarget.1652410.18632/oncotarget.16524 ↗
18. 10.1016/j.biopha.2017.09.01910.1016/j.biopha.2017.09.019 ↗
19. 10.18632/oncotarget.994810.18632/oncotarget.9948 ↗
20. 10.1038/cgt.2017.110.1038/cgt.2017.1 ↗
21. 10.1038/bjc.2011.52010.1038/bjc.2011.520 ↗
22. 10.1016/j.cell.2009.02.03810.1016/j.cell.2009.02.038 ↗
23. 10.1074/jbc.M111.25705510.1074/jbc.M111.257055 ↗
24. 10.2217/epi.13.7310.2217/epi.13.73 ↗
25. 10.3727/096504016X1473251078656410.3727/096504016X14732510786564 ↗